5 Reasons You Can’t Miss This Year’s Women In Bio – Capital Region’s HERstory Gala By Arielle Garcia | February 5, 2024 Dear BioBuzz and Women In Bio Members and [….]
5 Reasons You Can’t Miss This Year’s Women In Bio – Capital Region’s HERstory Gala
Weekly Quick Hits (BioHealth Capital Region) – Week of May 29, 2023
Weekly Quick Hits (BioHealth Capital Region) – Week of May 29, 2023 By Sarah EllinwoodJune 2, 2023 Funding, Awards and Collaborations BCWorld Healthcare and ReGelTec Enter Exclusive Distribution Agreement for [….]
Weekly Quick Hits (BioHealth Capital Region) – Week of April 24, 2023
Weekly Quick Hits (BioHealth Capital Region) – Week of April 24, 2023 By Sarah Ellinwood, Alex Keown, and Mark TerryApril 28, 2023 Funding, Awards and Collaborations Quest Diagnostics Acquires Haystack [….]
Weekly Quick Hits (BioHealth Capital Region) – Week of April 17, 2023
Weekly Quick Hits (BioHealth Capital Region) – Week of April 17, 2023 By Sarah Ellinwood, Alex Keown, and Mark TerryApril 21, 2023 Funding, Awards and Collaborations OpGen Enters Into Distribution [….]
Weekly Quick Hits (BioHealth Capital Region) – Week of April 3, 2023
Weekly Quick Hits (BioHealth Capital Region) – Week of April 3, 2023 By Sarah Ellinwood, Alex Keown, and Mark TerryApril 7, 2023 Funding, Awards and Collaborations Horizon Therapeutics Named to [….]
Weekly Quick Hits (BioHealth Capital Region) – Week of March 27, 2023
Weekly Quick Hits (BioHealth Capital Region) – Week of March 27, 2023 By Sarah Ellinwood, Alex Keown, and Mark TerryMarch 31, 2023 Funding, Awards and Collaborations 10Pearls Acquires Consulting Firm [….]
Precigen’s Experimental RRP Treatment Shows Early Signs of Promise
In January, the Germantown-based company announced positive data from a Phase I dose escalation and expansion cohort for the potential first-in-class PRGN-2012 off-the-shelf (OTS) AdenoVerse. Data shared by Precigen during its R&D Day presentation showed treatment with PRGN-2012 significantly reduced the need for surgeries for severe, aggressive RRP patients who received Dose Level 2 of the medication.
Weekly Quick Hits (BioHealth Capital Region) – Week of January 23, 2023
Here’s what’s been happening the BioHealth Capital Region’s Life Science scene the week of January 23, 2023
Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients
Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented positive Phase 1 dose escalation data from the ongoing Phase 1/1b clinical study of PRGN-3006 UltraCAR-T® in patients with r/r AML and higher risk myelodysplastic syndromes (MDS) (clinical trial identifier: NCT03927261) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract# 4633). The presentation was delivered by David A. Sallman, MD, Assistant Member in the Department of Malignant Hematology at the H. Lee Moffitt Cancer Center & Research Institute (Moffitt) and a lead investigator for the PRGN-3006 clinical trial.
Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company has entered into a definitive agreement for the sale of its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, L.C. (“Trans Ova”), an industry-leading animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership, for $170 million in upfront cash and up to $10 million earn-out based on the performance of Trans Ova in 2022 and 2023. Consummation of the transaction, anticipated in Q3 2022, is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.